ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
ㅁ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.
한글목차
올리고뉴클레오타이드 치료법 시장 규모는 향후 수년간 급성장할 것으로 전망됩니다. 2029년에 CAGR은 11.8%를 나타낼 것으로 예측되고 96억 6,000만 달러로 성장할 전망입니다. 예측 기간 동안의 성장은 연구 개발 투자, 전 세계 시장 진출, 치료 영역 확대, 질병 수정 전략, 규제 적응 등에 기인할 수 있습니다. 예측 기간의 주요 동향에는 맞춤형 치료법, 전달 시스템 발전, RNA 간섭(RNAi) 기술 진보, 안티센스 올리고뉴클레오타이드 혁신, 유전자 편집 기술 통합 등이 포함됩니다.
향후 5년간 11.8% 성장 전망은 이 시장에 대한 이전 추정치 대비 0.2% 소폭 하향 조정된 수치입니다. 이 하향 조정은 주로 미국과 타국 간 관세 영향 때문입니다. 관세 부과로 일본과 네덜란드에서 개발된 안티센스 올리고뉴클레오타이드 비용이 증가하여 미국 유전자 치료 발전이 저해될 수 있으며, 희귀질환 치료 지연 및 표적 치료제 개발 비용 상승을 초래할 수 있습니다. 또한 상호 관세 부과와 무역 긴장 및 제한 강화로 인한 전 세계 경제 및 무역에 대한 부정적 영향으로 그 파급 효과는 더욱 광범위해질 것입니다.
세계적인 암 환자 증가는 예측 기간 동안 올리고뉴클레오타이드 치료법 시장의 성장에 기여할 것으로 예측됩니다. 예를 들어, 2022년 1월 현재 미국암협회는 미국에서 약 190만명이 새롭게 암으로 진단되고, 60만9,360명이 암과 관련하여 사망하고, 하루 평균 약 1,670명이 사망할 것으로 예측했습니다. 폐암, 전립선암, 장암, 여성 유방암 등 세계적으로 가장 이환율이 높은 암종은 신규 암 이환 환자 전체의 43%를 차지하고 있습니다. 그 결과, 세계적인 암 이환율의 급증이 향후 몇 년간의 올리고뉴클레오타이드 치료법 시장 수요를 견인하게 됩니다.
목차
제1장 주요 요약
제2장 시장 특징
제3장 시장 동향과 전략
제4장 시장 - 거시경제 시나리오 금리, 인플레이션, 지정학, 무역전쟁과 관세, 그리고 코로나 및 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오
제5장 세계의 성장 분석과 전략 분석 프레임워크
세계의 올리고뉴클레오타이드 치료법 : PESTEL 분석(정치, 사회, 기술, 환경, 법적 요인, 촉진요인과 억제요인)
최종 이용 산업의 분석
세계의 올리고뉴클레오타이드 치료법 시장 : 성장률 분석
세계의 올리고뉴클레오타이드 치료법 시장 실적 : 규모와 성장(2019-2024년)
세계의 올리고뉴클레오타이드 치료법 시장 예측 : 규모와 성장(2024-2029년, 2034년)
세계의 올리고뉴클레오타이드 치료법 : 총 잠재시장 규모(TAM)
제6장 시장 세분화
세계의 올리고뉴클레오타이드 치료법 시장 : 유형별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
안티센스 올리고뉴클레오타이드
앱타머
기타 유형
세계의 올리고뉴클레오타이드 치료법 시장 : 용도별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
감염증
종양학
신경퇴행성 질환
심혈관 질환
신장병
기타 최종 사용자
세계의 올리고뉴클레오타이드 치료법 시장 : 최종 사용자별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
세계의 올리고뉴클레오타이드 치료법 시장, 기타 유형별 세분화 : 분석과 예측(2019-2024년, 2024-2029년, 2034년)
siRNA(저분자 간섭 RNA)
miRNA(마이크로RNA)
DNA자임과 리보자임
유전자 편집 합성 올리고뉴클레오타이드
제7장 지역별, 국가별 분석
세계의 올리고뉴클레오타이드 치료법 시장 : 지역별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
세계의 올리고뉴클레오타이드 치료법 시장 : 국가별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
제8장 아시아태평양 시장
제9장 중국 시장
제10장 인도 시장
제11장 일본 시장
제12장 호주 시장
제13장 인도네시아 시장
제14장 한국 시장
제15장 서유럽 시장
제16장 영국 시장
제17장 독일 시장
제18장 프랑스 시장
제19장 이탈리아 시장
제20장 스페인 시장
제21장 동유럽 시장
제22장 러시아 시장
제23장 북미 시장
제24장 미국 시장
제25장 캐나다 시장
제26장 남미 시장
제27장 브라질 시장
제28장 중동 시장
제29장 아프리카 시장
제30장 경쟁 구도와 기업 프로파일
올리고뉴클레오타이드 치료법 시장 : 경쟁 구도
올리고뉴클레오타이드 치료법 시장 : 기업 프로파일
Pfizer Inc. : 개요, 제품 및 서비스, 전략 및 재무 분석
Merck & Co. Inc. : 개요, 제품 및 서비스, 전략 및 재무 분석
GlaxoSmithKline plc : 개요, 제품 및 서비스, 전략 및 재무 분석
Gilead Sciences Inc. : 개요, 제품 및 서비스, 전략 및 재무 분석
BioNTech SE : 개요, 제품 및 서비스, 전략 및 재무 분석
제31장 기타 주요 기업 및 혁신 기업
Moderna Inc.
Biogen Inc.
Jazz Pharmaceuticals plc
QIAGEN Company
Alnylam Pharmaceuticals Inc.
Sarepta Therapeutics Inc.
Ionis Pharmaceuticals Inc.
Akcea Therapeutics Inc.
Arrowhead Pharmaceuticals Inc.
Dicerna Pharmaceuticals Inc.
SomaGenics Inc.
Wave Life Sciences Ltd.
Exicure Inc.
Avidity Biosciences Inc.
Miragen Therapeutics Inc.
제32장 세계 시장 경쟁 벤치마킹과 대시보드
제33장 주요 인수합병(M&A)
제34장 최근 시장 동향
제35장 시장의 잠재력이 높은 국가, 부문, 전략
올리고뉴클레오타이드 치료법 시장(2029년) : 새로운 기회를 제공하는 국가
올리고뉴클레오타이드 치료법 시장(2029년) : 새로운 기회를 제공하는 부문
올리고뉴클레오타이드 치료법 시장(2029년) : 성장 전략
시장 동향에 기초한 전략
경쟁 전략
제36장 부록
HBR
영문 목차
영문목차
Oligonucleotide therapy is a comprehensive term encompassing advanced molecular-targeting agents that utilize chemically synthesized oligonucleotides featuring single-stranded DNA (DNA) or RNA (RNA) backbones with inherent selectivity. Oligonucleotides are designed to form base pairs with DNA or RNA strands for various applications, with their most prevalent use being in PCR primers (polymerase chain reaction).
The primary categories of oligonucleotide therapy include antisense oligonucleotides, aptamers, and others. Antisense oligonucleotides (AS ONs) are artificial DNA oligomers designed to hybridize with a specific target RNA sequence. They have proven effective in limiting gene expression, modifying precursor messenger RNA splicing, and deactivating microRNAs. This therapeutic approach finds applications in infectious diseases, oncology, neurodegenerative disorders, cardiovascular diseases, kidney diseases, among others, and is applied in healthcare facilities and research institutes.
Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.
The sudden escalation of U.S. tariffs and the resulting trade tensions in spring 2025 are having a significant impact on the pharmaceutical sector. Companies are grappling with higher costs on imported active pharmaceutical ingredients (APIs), glass vials, and laboratory equipment-many of which have limited alternative sources. Generic drug manufacturers, already operating with minimal profit margins, are particularly affected, with some scaling back production of low-margin medications. Biotech firms are also experiencing delays in clinical trials due to shortages of specialized reagents linked to tariffs. In response, the industry is shifting API production to regions like India and Europe, building up inventory reserves, and advocating for tariff exemptions on essential medicines.
The oligonucleotide therapy market research report is one of a series of new reports from The Business Research Company that provides oligonucleotide therapy market statistics, including oligonucleotide industry global market size, regional shares, competitors with an oligonucleotide market share, detailed oligonucleotide therapy market segments, market trends, and opportunities, and any further data you may need to thrive in the oligonucleotide industry. This oligonucleotide therapy market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.
The oligonucleotide therapy market size has grown rapidly in recent years. It will grow from $5.61 billion in 2024 to $6.2 billion in 2025 at a compound annual growth rate (CAGR) of 10.5%. The growth in the historic period can be attributed to growth in investment in research and development, market entry of early therapies, rise of gene editing techniques, early therapeutic discoveries, rnai and antisense oligonucleotide introduction.
The oligonucleotide therapy market size is expected to see rapid growth in the next few years. It will grow to $9.66 billion in 2029 at a compound annual growth rate (CAGR) of 11.8%. The growth in the forecast period can be attributed to research and development investments, global market penetration, therapeutic area expansion, disease modification strategies, regulatory adaptations. Major trends in the forecast period include customized therapies, advancements in delivery systems, rna interference (RNAI) advancements, antisense oligonucleotide innovation, gene editing techniques integration.
The forecast of 11.8% growth over the next five years reflects a modest reduction of 0.2% from the previous estimate for this market. This reduction is primarily due to the impact of tariffs between the US and other countries. The imposition of tariffs may hinder U.S. genetic medicine progress by increasing costs of antisense oligonucleotides developed in Japan and the Netherlands, potentially delaying rare disease treatments and raising targeted therapy development expenses. The effect will also be felt more widely due to reciprocal tariffs and the negative effect on the global economy and trade due to increased trade tensions and restrictions.
The increase in cancer cases globally is expected to contribute to the oligonucleotide therapy market's growth during the forecast period. For example, as of January 2022, the American Cancer Society projected approximately 1.9 million new cancer diagnoses and 609,360 cancer-related deaths in the US, averaging around 1,670 fatalities daily. The most prevalent cancer types globally-lung, prostate, bowel, and female breast cancer-constitute 43% of all new cancer cases. Consequently, the surge in global cancer incidence rates is poised to drive the oligonucleotide therapy market's demand in the coming years.
Government initiatives aimed at research and development in healthcare are anticipated to boost the oligonucleotide therapy market's growth. These initiatives involve specific actions, programs, policies, or projects undertaken by government authorities at various levels (local, regional, national, or international) to address specific issues, achieve defined goals, or instigate positive changes in society. Various government bodies are launching healthcare initiatives to support different aspects, including oligonucleotide therapy. In 2022, the UK government, as per the Department of Health and Social Care, committed £260 million (US $270.65 million) in funding to enhance healthcare research and manufacturing. This funding, provided by BEIS and DHSC, aimed to support NHS-led health research in diagnostics and treatment through new privacy-preserving platforms and clinical research services. Additionally, £60 million (US $63.60 million) was allocated to assist in expanding life sciences manufacturing in the UK.
Developers and providers in the oligonucleotide therapy market are investing in research and development to redesign therapy approaches. Innovative oligonucleotides enable precision medicine, selectively targeting genes with minimal side effects, and addressing patient-specific sequences causing rare diseases. In April 2023, the FDA approved Qalsody, an antisense oligonucleotide (ASO), for treating ALS associated with the SOD1 gene mutation. Qalsody targets SOD1 mRNA to reduce protein synthesis.
Major companies in the oligonucleotide therapy market are introducing pediatric-focused therapies to drive market revenues. Elevidys, the first FDA-approved gene therapy for Duchenne muscular dystrophy (DMD) in pediatric patients aged 4 through 5, showcases advancements in gene-based treatments for genetic diseases, although not specifically an oligonucleotide therapy.
In September 2022, Vanda Pharmaceuticals, a US-based biopharmaceutical company, and OliPass, a South Korea-based biotechnology company, announced a strategic partnership to develop antisense oligonucleotide (ASO) therapeutics. This collaboration aims to jointly develop a series of ASO molecules based on OliPass' proprietary modified peptide nucleic acids, leveraging the strengths of both companies to advance ASO-based precision medicine therapeutics.
North America was the largest region in the oligonucleotide therapy market in 2024. The regions covered in the oligonucleotide therapy market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
The countries covered in the oligonucleotide therapy market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain
The oligonucleotide therapy market consists of sales of ASOs, siRNAs, miRNAs, and DNAzymes. Values in this market are factory gate values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Oligonucleotide Therapy Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses on oligonucleotide therapy market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase
Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, post-pandemic supply chain realignment, inflation and interest rate fluctuations, and evolving regulatory landscapes.
Create regional and country strategies on the basis of local data and analysis.
Identify growth segments for investment.
Outperform competitors using forecast data and the drivers and trends shaping the market.
Understand customers based on the latest market shares.
Benchmark performance against key competitors.
Suitable for supporting your internal and external presentations with reliable high quality data and analysis
Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
All data from the report will also be delivered in an excel dashboard format.
Where is the largest and fastest growing market for oligonucleotide therapy ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The oligonucleotide therapy market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
The market characteristics section of the report defines and explains the market.
The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
The forecasts are made after considering the major factors currently impacting the market. These include:
The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
Market segmentations break down the market into sub markets.
The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Scope
Markets Covered:1) By Type: Antisense Oligonucleotide; Aptamer; Other Types
2) By Application: Infectious Diseases; Oncology; Neurodegenerative Disorders; Cardiovascular Diseases; Kidney Diseases; Other End-User
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: PDF, Word and Excel Data Dashboard.
Table of Contents
1. Executive Summary
2. Oligonucleotide Therapy Market Characteristics
3. Oligonucleotide Therapy Market Trends And Strategies
4. Oligonucleotide Therapy Market - Macro Economic Scenario Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market
4.1. Supply Chain Impact from Tariff War & Trade Protectionism
5. Global Oligonucleotide Therapy Growth Analysis And Strategic Analysis Framework
5.1. Global Oligonucleotide Therapy PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
5.2. Analysis Of End Use Industries
5.3. Global Oligonucleotide Therapy Market Growth Rate Analysis
5.4. Global Oligonucleotide Therapy Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
5.5. Global Oligonucleotide Therapy Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
5.6. Global Oligonucleotide Therapy Total Addressable Market (TAM)
6. Oligonucleotide Therapy Market Segmentation
6.1. Global Oligonucleotide Therapy Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Antisense Oligonucleotide
Aptamer
Other Types
6.2. Global Oligonucleotide Therapy Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Infectious Diseases
Oncology
Neurodegenerative Disorders
Cardiovascular Diseases
Kidney Diseases
Other End-User
6.3. Global Oligonucleotide Therapy Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Hospitals
Research Institutes
6.4. Global Oligonucleotide Therapy Market, Sub-Segmentation Of Antisense Oligonucleotide, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
RNA-Targeted Antisense Oligonucleotides
DNA-Targeted Antisense Oligonucleotides
Chemically Modified Antisense Oligonucleotides
6.5. Global Oligonucleotide Therapy Market, Sub-Segmentation Of Aptamer, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
DNA Aptamers
RNA Aptamers
Small Molecule Aptamers
6.6. Global Oligonucleotide Therapy Market, Sub-Segmentation Of Other Types, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
siRNA (Small Interfering RNA)
miRNA (Micro RNA)
DNAzyme And Ribozymes
Synthetic Oligonucleotides For Gene Editing
7. Oligonucleotide Therapy Market Regional And Country Analysis
7.1. Global Oligonucleotide Therapy Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
7.2. Global Oligonucleotide Therapy Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
